Table 1 Descriptive characteristics by detection method 1999–2016 (n = 6603)
From: Breast cancer distant recurrence lead time interval by detection method in an institutional cohort
| PtD | MamD | p value | |
|---|---|---|---|
| (n = 2566) | (n = 4037) | ||
| Stage | N (column %) | N (column %) | |
| I | 792 (31%) | 2772 (69%) | <.001 |
| II | 1314 (51%) | 1108 (27%) | |
| III | 460 (18%) | 157 (4%) | |
| Age | |||
| 40–49 | 950 (55%) | 765 (45%) | <.001 |
| 50–64 | 1216 (36%) | 2189 (64%) | |
| 65–74 | 400 (27%) | 1083 (73%) | |
| Mean age (range, F statistic) | 54 (40–74) | 58 (40–74) | <.001 |
| Race | |||
| White | 1986 (37%) | 3388 (63%) | <.001 |
| Non-White | 580 (47%) | 649 (53%) | |
| Hormone receptor status | |||
| HR+ | 2081 (36%) | 3641 (64%) | <.001 |
| HER2 status | |||
| Her2+ (HR- or HR+) | 458 (46%) | 534 (54%) | <.001 |
| HR/HER2 status at initial diagnosis | |||
| HR+/HER2- | 1718 (36%) | 3110 (64%) | <.001 |
| HR+/HER2+ | 332 (45%) | 399 (55%) | |
| HR−/HER2- | 340 (61%) | 216 (39%) | |
| HR−/HER2+ | 126 (49%) | 134 (51%) | |
| Histologic type initial primary breast tumor | |||
| Ductal | 2122 (39%) | 3312 (61%) | .287 |
| Lobular | 258 (39%) | 411 (61%) | |
| Lobular/Ductal mixed | 120 (40%) | 177 (60%) | |
| Other cancer | 64 (33%) | 133 (67%) | |
| Nuclear grade initial primary breast tumor | |||
| Low/Intermediate | 1189 (31%) | 2675 (69%) | <.001 |
| High | 1340 (51%) | 1289 (49%) | |
| Histologic grade initial primary breast tumor | |||
| Low/Intermediate | 583 (29%) | 1447 (71%) | <.001 |
| High | 1943 (44%) | 2498 (56%) | |
| Tumor size (mean, range, F statistic) | 2.91 (.10, 18.00) | 1.51 (.05, 17.00) | <.001 |
| # Positive nodes (mean, range, F statistic) | 1.67 (0–44) | .57 (0–35) | <.001 |
| Treatment | |||
| Surgery only | 339 (36%) | 614 (64%) | <.001 |
| Surgery/radiation | 575 (22%) | 1997 (78%) | |
| Surgery/chemotherapy | 412 (53%) | 372 (47%) | |
| Surgery/radiation/chemotherapy | 1240 (54%) | 1054 (46%) | |
| Distant recurrence | |||
| Yes | 289 (68%) | 133 (32%) | <.001 |
